GB0309009D0 - Quinazoline derivatives - Google Patents

Quinazoline derivatives

Info

Publication number
GB0309009D0
GB0309009D0 GBGB0309009.9A GB0309009A GB0309009D0 GB 0309009 D0 GB0309009 D0 GB 0309009D0 GB 0309009 A GB0309009 A GB 0309009A GB 0309009 D0 GB0309009 D0 GB 0309009D0
Authority
GB
United Kingdom
Prior art keywords
quinazoline derivatives
effect
tyrxosine
quinazsoline
animnal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0309009.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0309009.9A priority Critical patent/GB0309009D0/en
Publication of GB0309009D0 publication Critical patent/GB0309009D0/en
Priority to CA002526897A priority patent/CA2526897A1/en
Priority to ES04728367T priority patent/ES2329576T3/es
Priority to EP04728367A priority patent/EP1631292B1/en
Priority to JP2006506155A priority patent/JP2006524218A/ja
Priority to HK06107909.9A priority patent/HK1087632B/en
Priority to KR1020057020096A priority patent/KR20060006821A/ko
Priority to MXPA05011332A priority patent/MXPA05011332A/es
Priority to US10/554,202 priority patent/US20070149546A1/en
Priority to NZ543015A priority patent/NZ543015A/en
Priority to PCT/GB2004/001713 priority patent/WO2004093880A1/en
Priority to AU2004231349A priority patent/AU2004231349A1/en
Priority to CNB2004800170469A priority patent/CN100406453C/zh
Priority to DE602004022404T priority patent/DE602004022404D1/de
Priority to BRPI0409633-9A priority patent/BRPI0409633A/pt
Priority to AT04728367T priority patent/ATE438402T1/de
Priority to ZA200508525A priority patent/ZA200508525B/en
Priority to NO20054856A priority patent/NO20054856L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0309009.9A 2003-04-22 2003-04-22 Quinazoline derivatives Ceased GB0309009D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0309009.9A GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives
AT04728367T ATE438402T1 (de) 2003-04-22 2004-04-20 4-anilino-chinazolin-derivate als proliferationshemmende mittel
US10/554,202 US20070149546A1 (en) 2003-04-22 2004-04-20 4-Anilino-quinazoline derivatives as antiproliferative agents
PCT/GB2004/001713 WO2004093880A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
EP04728367A EP1631292B1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
JP2006506155A JP2006524218A (ja) 2003-04-22 2004-04-20 増殖抑制薬としての４−アニリノキナゾリン誘導体
HK06107909.9A HK1087632B (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
KR1020057020096A KR20060006821A (ko) 2003-04-22 2004-04-20 항증식제로서의 4-아닐리노-퀴나졸린 유도체
MXPA05011332A MXPA05011332A (es) 2003-04-22 2004-04-20 Derivados de 4-anilino-quinazolina como agentes antiproliferativos.
CA002526897A CA2526897A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
NZ543015A NZ543015A (en) 2003-04-22 2004-04-20 4-Anilino-quinazoline derivatives for producing antiproliferative effect by inhibiting erbB2 receptor tyrosine kinase
ES04728367T ES2329576T3 (es) 2003-04-22 2004-04-20 Derivados de 4-anilino-quinazolina como agentes antiproliferativos.
AU2004231349A AU2004231349A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
CNB2004800170469A CN100406453C (zh) 2003-04-22 2004-04-20 抗增殖药4-苯胺基-喹唑啉衍生物
DE602004022404T DE602004022404D1 (de) 2003-04-22 2004-04-20 4-anilino-chinazolin-derivate als proliferationshemmende mittel
BRPI0409633-9A BRPI0409633A (pt) 2003-04-22 2004-04-20 derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina
NO20054856A NO20054856L (no) 2003-04-22 2005-10-20 4-anilino-kinazolinderivater som antiproliferative midler
ZA200508525A ZA200508525B (en) 2003-04-22 2005-10-20 4-Anilino-quinazoline derivatives as antiproliferative agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0309009.9A GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
GB0309009D0 true GB0309009D0 (en) 2003-05-28

Family

ID=9957022

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0309009.9A Ceased GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives

Country Status (17)

Country Link
US (1) US20070149546A1 (https=)
EP (1) EP1631292B1 (https=)
JP (1) JP2006524218A (https=)
KR (1) KR20060006821A (https=)
CN (1) CN100406453C (https=)
AT (1) ATE438402T1 (https=)
AU (1) AU2004231349A1 (https=)
BR (1) BRPI0409633A (https=)
CA (1) CA2526897A1 (https=)
DE (1) DE602004022404D1 (https=)
ES (1) ES2329576T3 (https=)
GB (1) GB0309009D0 (https=)
MX (1) MXPA05011332A (https=)
NO (1) NO20054856L (https=)
NZ (1) NZ543015A (https=)
WO (1) WO2004093880A1 (https=)
ZA (1) ZA200508525B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260164A (zh) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
CA2527017A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
AU2004272345A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
AU2004272346A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
ES2305844T3 (es) * 2003-09-16 2008-11-01 Astrazeneca Ab Derivados de quinazolina como inhibidores de tirosina cinasa.
US20070032508A1 (en) * 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP5032851B2 (ja) 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ キナゾリン誘導体
AU2005250224A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as ERBB receptor tyrosine kinases
EP1838712B8 (en) * 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
JP2009517450A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
JP2009517451A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ Ｅｒｂｂチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009057139A2 (en) 2007-10-29 2009-05-07 Natco Pharma Limited Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8055334B2 (en) * 2008-12-11 2011-11-08 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
TW321649B (https=) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100517060B1 (ko) * 1996-01-31 2006-05-25 코스모페름 베.파우 안정화된생물학적유효화합물로이루어지는조성물의사용
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
DE19651439A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Polymerisierbare Biaryle, Verfahren zur Herstellung und deren Verwendung
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
TR200102505T2 (tr) * 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
JP2007500177A (ja) * 2003-07-29 2007-01-11 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
ES2305844T3 (es) * 2003-09-16 2008-11-01 Astrazeneca Ab Derivados de quinazolina como inhibidores de tirosina cinasa.
AU2004272346A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
US20070032508A1 (en) * 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
KR20060100388A (ko) * 2003-09-25 2006-09-20 아스트라제네카 아베 퀴나졸린 유도체
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP5032851B2 (ja) * 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ キナゾリン誘導体
AU2005250224A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as ERBB receptor tyrosine kinases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260164A (zh) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用
CN115260164B (zh) * 2021-05-01 2024-03-26 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用

Also Published As

Publication number Publication date
NO20054856L (no) 2005-11-21
WO2004093880A1 (en) 2004-11-04
CA2526897A1 (en) 2004-11-04
DE602004022404D1 (de) 2009-09-17
ES2329576T3 (es) 2009-11-27
ATE438402T1 (de) 2009-08-15
CN100406453C (zh) 2008-07-30
ZA200508525B (en) 2007-04-25
HK1087632A1 (en) 2006-10-20
EP1631292A1 (en) 2006-03-08
CN1809360A (zh) 2006-07-26
US20070149546A1 (en) 2007-06-28
BRPI0409633A (pt) 2006-04-25
EP1631292B1 (en) 2009-08-05
NO20054856D0 (no) 2005-10-20
KR20060006821A (ko) 2006-01-19
JP2006524218A (ja) 2006-10-26
AU2004231349A1 (en) 2004-11-04
MXPA05011332A (es) 2005-11-28
NZ543015A (en) 2008-01-31

Similar Documents

Publication Publication Date Title
GB0309009D0 (en) Quinazoline derivatives
MX2009010595A (es) Derivados de pirrolopirimidina.
MX2009007302A (es) Derivados de purina.
NO20061321L (no) Kinazolinderivater som tyrosin kinase inhibitorer
MX2009009774A (es) Derivados de quinolina como fungicidas.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
SG170739A1 (en) Iap bir domain binding compounds
MX2009011199A (es) Derivados de pirimidina.
MEP0508A (xx) Derivati pirimidina
SG163585A1 (en) Melanocortin receptor ligands
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
TW200800956A (en) 2-Aminopyrimidine derivatives
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
UA101963C2 (en) 4-amino-pyrimidine derivatives
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
UY28610A1 (es) Derivados de quinazolina
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
TW200607805A (en) Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
ATE438641T1 (de) Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase
GB0508715D0 (en) Chemical compounds
EP1838712B8 (en) Pyrazolopyrimidine compounds as antitumor agents
TW200745090A (en) Chemical compounds
IL186034A0 (en) Pyrimidine derivatives for use as anticancer agents
SI1893589T1 (sl) Substituirani N-benzo(d)izoksazol-3-il-aminski derivati kot inhibitorji mGluR5, serotonin-(5-HT) in noradrenalinskih receptorjev in njihova uporaba za pripravo zdravil

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)